Core Insights - Labcorp has appointed Dr. John H. Sampson to its Board of Directors, effective February 9, 2026, bringing extensive experience in clinical care, biomedical research, and health system leadership [1][2] Group 1: Appointment Details - Dr. Sampson is currently the vice chancellor for health affairs and dean at the University of Colorado Anschutz School of Medicine, recognized for his expertise in oncology, neuroscience, women's health, and personalized medicine [1][2] - He has previously held senior leadership roles at Duke University Health System, where he was senior vice president and led the Duke Health Integrated Practice [2] Group 2: Strategic Impact - Dr. Sampson's expertise is expected to advance Labcorp's strategy in diagnostics and drug development, enhancing the value delivered to customers [2] - He has authored nearly 300 peer-reviewed publications focused on advancing new therapies for neurologic diseases, which aligns with Labcorp's mission [2] Group 3: Company Overview - Labcorp is a global leader in laboratory services, providing insights and advancing science to improve health, with nearly 70,000 employees serving clients in approximately 100 countries [4] - The company supports over 75% of new drugs and therapeutic products approved by the FDA in 2024 and performs more than 700 million tests annually [4]

Group 1 - Labcorp will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 4:30 p.m. PT [1] - A live audio webcast of the fireside chat will be available on the Company Investor Relations website and archived for replay [1] Group 2 - Labcorp is a global leader in laboratory services, providing insights and advancing science to improve health [2] - The company employs nearly 70,000 people and serves clients in approximately 100 countries [2] - Labcorp supported over 75% of new drugs and therapeutic products approved by the FDA in 2024 and performs more than 700 million tests annually [2]

Core Insights - Labcorp, a global leader in laboratory services, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025 [1] - A live audio webcast of the event will be available on the Company Investor Relations website and archived for later replay [1] Company Overview - Labcorp provides innovative and comprehensive laboratory services to assist doctors, hospitals, pharmaceutical companies, researchers, and patients in making informed decisions [2] - The company employs nearly 70,000 individuals and serves clients in approximately 100 countries [2] - Labcorp supported over 75% of new drugs and therapeutic products approved by the FDA in 2024 and conducts more than 700 million tests annually [2]